Blood cancers

Improved clinical trial survival rates in HL explained by age

The superior survival seen among patients with Hodgkin Lymphoma treated in clinical trials can be largely explained by the differences in baseline characteristics, particularly younger age, 20 year results from the EORTC-Netherlands cancer registry show. People with Hodgkin lymphoma who were treated as part of a clinical trial had an 8% superior crude 10-year overall survival compared ...

Already a member?

Login to keep reading.

© 2021 the limbic